|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Sunday
MSF Home: LINKThe FDA has added a warning to the labeling of Novantrone that includes additional information about the potential risk of heart damage (cardiotoxicity) and a form of leukemia (secondary acute myelogenous leukemia - AML).
The new FDA labeling requires repeat testing of cardiac function prior to each dose, in addition to the baseline testing of cardiac function which was recommended by the original labeling of Novantrone. |